GSK taps EMD Serono’s Martinez-Davis as U.S. pharmaceuticals president

Press enter to search
Close search
Open Menu

GSK taps EMD Serono’s Martinez-Davis as U.S. pharmaceuticals president

By Sandra Levy - 08/15/2019
GSK is making changes at the helm of its U.S. pharmaceuticals business. Jack Bailey, president of U.S. Pharmaceuticals, will be stepping down at the end of the year, to be succeeded by Maya Martinez-Davis, currently regional president for the Latin America region at EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany.

“Jack is an exceptional leader who has made a very significant contribution to the success of GSK during his decade of leadership in the United States," GSK president global pharmaceuticals Luke Miels said. “As we continue to grow and reshape our business globally, we are pleased to have found a leader in Maya who will bring a valuable U.S. experience and deep therapy area expertise to expanding our specialty care capabilities and market presence.”

GSK noted that Martinez-Davis has a track record of bringing new specialty treatments to market, a background that she will bring to the company as it focuses on an expanded pipeline and new oncology medicines. Before her work with EMD Serono, Martinez-Davis spent 13 years with Pfizer, heading up various worldwide business units, including oncology and vaccines.

Martinez-Davis will join GSK in mid-September and will assume responsibility of the U.S. pharmaceuticals business on Jan. 1, 2020. Bailey will remain as a strategic consultant to GSK through 2020.

“After more than a decade at GSK and nearly three decades in the life sciences industry, I look forward to the chance to explore my next professional chapter," Bailey said. "I am enormously proud of every GSK U.S. colleague who has worked so hard to both navigate an exceptionally dynamic operating environment while returning the U.S. affiliate to double-digit revenue growth these past several years. I am confident the company will build upon the talent, culture and performance success of the U.S. affiliate as it now expands its portfolio into oncology."